Dalcetrapib
10mM in DMSO
- Product Code: 168721
CAS:
211513-37-0
| Molecular Weight: | 389.59 g./mol | Molecular Formula: | C₂₃H₃₅NO₂S |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD06407886 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
Dalcetrapib is a cholesteryl ester transfer protein (CETP) inhibitor developed to improve cardiovascular outcomes by increasing high-density lipoprotein (HDL) cholesterol levels. It was investigated for use in patients with established cardiovascular disease to reduce the risk of atherosclerotic events such as heart attack and stroke. The compound aimed to shift the balance of lipid metabolism by blocking the transfer of cholesterol esters from HDL to low-density lipoprotein (LDL), thereby promoting reverse cholesterol transport.
Clinical trials focused on its ability to raise HDL cholesterol and potentially regress plaque formation in arteries. However, large outcome studies did not demonstrate significant reduction in cardiovascular events, leading to discontinuation of its development. Despite the lack of clinical benefit observed, dalcetrapib contributed to research on HDL-targeted therapies and the complex role of HDL in cardiovascular health.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿13,390.00 |
+
-
|
Dalcetrapib
Dalcetrapib is a cholesteryl ester transfer protein (CETP) inhibitor developed to improve cardiovascular outcomes by increasing high-density lipoprotein (HDL) cholesterol levels. It was investigated for use in patients with established cardiovascular disease to reduce the risk of atherosclerotic events such as heart attack and stroke. The compound aimed to shift the balance of lipid metabolism by blocking the transfer of cholesterol esters from HDL to low-density lipoprotein (LDL), thereby promoting reverse cholesterol transport.
Clinical trials focused on its ability to raise HDL cholesterol and potentially regress plaque formation in arteries. However, large outcome studies did not demonstrate significant reduction in cardiovascular events, leading to discontinuation of its development. Despite the lack of clinical benefit observed, dalcetrapib contributed to research on HDL-targeted therapies and the complex role of HDL in cardiovascular health.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :